Valeo Pharma Inc
TSX:VPH

Watchlist Manager
Valeo Pharma Inc Logo
Valeo Pharma Inc
TSX:VPH
Watchlist
Price: 0.045 CAD Market Closed
Market Cap: 4.4m CAD

Net Margin
Valeo Pharma Inc

-60.2%
Current
-80%
Average
3.8%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-60.2%
=
Net Income
-32.1m
/
Revenue
53.4m

Net Margin Across Competitors

No Stocks Found

Valeo Pharma Inc
Glance View

Market Cap
4.4m CAD
Industry
N/A

Valeo Pharma, Inc. engages in the acquisitions, in-licensing or similar arrangements of patent protected, pharmaceutical products in specific therapeutic areas for the Canadian market. The company is headquartered in Kirkland, Quebec and currently employs 100 full-time employees. The company went IPO on 2019-02-20. The firm acquires or in-licenses brand and hospital specialty products for sale in Canada. The firm is focused on four therapeutic areas, which includes respiratory, oncology, specialty products and neurology. Its respiratory product is Enerzair breezhaler and Atectura breezhaler; its oncology product is Yondelis; its specialty product includes Redesca, Ametop Gel, and M-Eslon and its neurology product is Onstryv. The firm has eight marketed brands and four additional products. Its wholly owned subsidiary is VPI Pharmaceuticals Inc.(VPI).

VPH Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-60.2%
=
Net Income
-32.1m
/
Revenue
53.4m
What is the Net Margin of Valeo Pharma Inc?

Based on Valeo Pharma Inc's most recent financial statements, the company has Net Margin of -60.2%.

Back to Top